

CLINICAL STUDY FOR PATIENTS WITH RET+ SOLID TUMOURS

EP0031 is a novel experimental drug which has the potential to overcome resistance that some cancers can develop to first generation selective RET inhibitors, it's being investigated in a Phase 1/2 study in the US and EU

DOSE FINDING MODULE

ENROLLING NOW

Patients will receive different doses of the study drug to find out which is best to give to adult patients with RET-altered solid tumours

1. All patients with RET altered solid tumours
2. Patients may be enrolled regardless of whether they have been previously treated with an SRI
3. Patients with spinal cord compression, stable brain metastasis or those living with HIV may be enrolled

CLINIC VISITS

1. Cycle 1: Five visits to clinic
2. Subsequent cycles: Two visits to clinic
3. Each cycle is 28 days long
4. Patient expenses will be reimbursed

Study has planned expansion cohorts

Active Site	Contact
Site 1: UCLA (USA)	agianoukakis@lundquist.org
Site 2: Providence Portland Medical Centre (USA)	matthew.taylor@providence.org
Site 3: University of Kentucky (USA)	susanne.arnold@uky.edu
Site 4: MD Anderson Cancer Center (USA)	vsubbiah@mdanderson.org
Site 5: Vall d'Hebron (Spain)	egarralda@vhio.net
Site 6: Ramon y Cajal (Spain)	pgarrido@salud.madrid.org

New sites are being recruited
please scan QR for updates

